Spontaneous synchronous bilateral hemothorax as the only finding in primary pleural angiosarcoma: a case report and a literature review

Levi, Guido; Orzes, Nicla; Uccelli, Silvia; Cettolo, Francesca; Arici, Marianna; Ciarfaglia, Manuela; Fisogni, Simona; Marchetti, Giampietro; Rocchetti, Chiara

doi:10.4081/monaldi.2021.1520

Cited by 2 publications

(3 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Angiosarcoma can affect several organs [ 45 , 46 ] and usually appears in the pleura as a metastasis from other tissues [ 47 ]. Primary pleural angiosarcoma (PPA) is extremely rare and displays heterogeneous clinical presentation [ 45 , 46 , 47 ]. The diagnosis is usually set based on the biopsy results [ 45 , 48 ].…”

Section: Pleural Neoplasms and Their Classificationmentioning

confidence: 99%

“…The diagnosis is usually set based on the biopsy results [ 45 , 48 ]. The treatment involves surgical resection, radiotherapy, or chemotherapy [ 45 , 46 , 48 ]. Based on the limited number of reported cases, the 2-year survival rate for patients with PPA seems to be around 4.4% with a median overall survival of 4 months [ 48 ].…”

Section: Pleural Neoplasms and Their Classificationmentioning

confidence: 99%

“…PEH is more aggressive than other EH subtypes [ 140 ] and the prognosis in the case of PEH is generally much worse than for pulmonary EH [ 139 ]. The sex and age of the patients could potentially point the physicians in the right direction, as the PEH is more often observed in older men, while the pulmonary EH is primarily observed in young and middle-aged women [ 46 , 47 , 48 ]. Exposure to radiation or to asbestos is considered a risk factor and its confirmation could be helpful in establishing the diagnosis [ 140 ].…”

Section: Mri As a Diagnostic Tool In Pleural Neoplasmsmentioning

confidence: 99%

See 2 more Smart Citations

Pleural Neoplasms—What Could MRI Change?

Szczyrek

Bitkowska

Jutrzenka

et al. 2023

Cancers

View full text Add to dashboard Cite

The primary pleural neoplasms constitute around 10% of the pleural tumors. The currently recommended method for their imaging is CT which has been shown to have certain limitations. Strong development of the MRI within the last two decades has provided us with a number of sequences that could potentially be superior to CT when it comes to the pleural malignancies’ detection and characterization. This literature review discusses the possible applications of the MRI as a diagnostic tool in patients with pleural neoplasms. Although selected MRI techniques have been shown to have a number of advantages over CT, further research is required in order to confirm the obtained results, broaden our knowledge on the topic, and pinpoint the sequences most optimal for pleural imaging, as well as the best methods for reading and analysis of the obtained data.

show abstract

Section: Pleural Neoplasms and Their Classificationmentioning

confidence: 99%

Section: Pleural Neoplasms and Their Classificationmentioning

confidence: 99%

Section: Mri As a Diagnostic Tool In Pleural Neoplasmsmentioning

confidence: 99%

See 1 more Smart Citation

Pleural Neoplasms—What Could MRI Change?

Szczyrek

Bitkowska

Jutrzenka

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

The Outcome of SARS-CoV-2 Infection in Patients with Lymphoma and the Risk Factors for the Development of Pneumonia

Hong,

Choi,

Jeon

et al. 2024

Infect Chemother

View full text Add to dashboard Cite

Background Although patients with lymphoma appear particularly vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the clinical evolution of coronavirus disease 2019 (COVID-19) in a patient with lymphoid malignancies has been under-represented, especially in relation to chemo-, chemo-immunotherapy. Materials and Methods Among adult patients with lymphoma receiving treatment in a specialized lymphoma center at a 500-bed, university-affiliated hospital, we retrospectively reviewed the medical records of patients diagnosed with SARS-CoV-2 infection from January 2020 to April 2022. Results A total of 117 patients with a median age of 53 years were included. One hundred twelves (95.7%) were non-Hodgkin lymphoma. Eighty-six patients (73.5%) were on active chemotherapy and 9 were post stem cell transplant state. Sixty-one patients had more than one comorbidity and 29 had hypogammaglobulinemia. Thirty-four patients (29.1%) had never received a COVID-19 vaccine. During a median follow-up of 134 days, COVID-19 pneumonia developed in 37 patients (31.6%). Excluding three patients who died before the 30 days, 31 out of 34 patients had ongoing symptomatic COVID-19. Eleven patients (9.4%) had post COVID-19 lung condition that persisted 90 days after COVID-19 diagnosis. Overall mortality was 10.3% (12 of 117), which was higher in patients with pneumonia. In multivariate analyses, age 65 years or older, follicular lymphoma, receiving rituximab maintenance therapy, and lack of vaccination were significantly associated with the development of COVID-19 pneumonia. Conclusion Patients with lymphoma are at high risk for developing pneumonia after SARS-CoV-2 infection and suffer from prolonged symptoms. More aggressive vaccination and protective measures for patients with lymphoma who have impaired humoral response related to rituximab maintenance therapy and hypogammaglobulinemia are needed.

show abstract

Spontaneous synchronous bilateral hemothorax as the only finding in primary pleural angiosarcoma: a case report and a literature review

Cited by 2 publications

References 4 publications

Pleural Neoplasms—What Could MRI Change?

Pleural Neoplasms—What Could MRI Change?

The Outcome of SARS-CoV-2 Infection in Patients with Lymphoma and the Risk Factors for the Development of Pneumonia

Contact Info

Product

Resources

About